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Chronic spontaneous urticaria (CSU) is characterized by
the recurrent appearance of weals, angio-oedema or both,
occurring at least twice weekly for longer than 6 weeks.1
It is often managed with antihistamines, but occasionally
requires other systemic agents in recalcitrant cases.
A cross-sectional survey was conducted by means of
an internet-based survey tool (Typeform; https://www.
typeform.com). Participating consultants with a specialist
interest in urticaria were identified through the specialist
registers of the British Society of Allergy and Clinical
Immunology (BSACI), the Improving Quality in Allergy
Services (IQAS) Group and the British Association of Der-
matologists (BAD), and invited to take part.
The survey content was based on current CSU treat-
ment guidelines from EAACI/GA2LEN/EDF/WAO1 and the
British Society for Allergy and Clinical Immunology
(BSACI).2 The EAACI/GA2LEN/EDF/WAO guidelines are a
joint initiative of the Dermatology Section of the European
Academy of Allergy and Clinical Immunology (EAACI), the
Global Allergy and Asthma European Network (GA2LEN)
(a European Union-funded network of excellence), the
European Dermatology Forum (EDF), and the World
Allergy Organization (WAO). To standardize responses, all
participants were presented with a case of recalcitrant CSU
(failed on maximum dose of nonsedating antihistamines
and montelukast), requiring alternative systemic treat-
ment. Questions covered usage of systemic treatments,
routine disease severity assessments, adherence to treat-
ment guidelines and perceived barriers to prescribing.
Responses (Table 1) were received from 19 UK consul-
tants (26 surveys sent; completion rate 73%), 15 of
whom had > 10 years’ experience in the treatment of
CSU. The majority were allergy (58%) and dermatology
consultants (37%). Of the 19 consultants, 56% provide a
dedicated urticaria service, 37% treat both adult and pae-
diatric patients, and the majority (79%) use systemic
medications other than antihistamines and montelukast.
Omalizumab and ciclosporin were the most commonly
used first-line agents (47% and 27% respectively) (Fig. 1).
The majority (84%) of consultants use validated measures
to assess disease severity, including the weekly Urticaria
Table 1 Summary of survey results.
Parameter Response, % (n)
Section 1: Demographics
Country of work
United Kingdom 100% (19)
Hospital grade
Consultant 100% (19)
Specialty
Allergy 58% (11)
Dermatology 37% (7)
Immunology 5% (1)
Caseload
Adult only 42% (8)
Both adult and paediatric 37% (7)
Paediatric only 21% (4)
Number of years in specialty
> 20 53% (10)
10–20 26% (5)
< 10 21% (4)
Section 2: Use of systemic medications
Do you use systemic medication for the management of chronic
urticaria?
Yes 79% (15)
No 21% (4)
First-line treatments?
Omalizumab 47% (7)
Ciclosporin 28% (4)
Other 20% (3)
Dapsone 7% (1)
Second-line treatments?
Omalizumab 40% (6)
Ciclosporin 33% (5)
Mycophenolate mofetil 13% (2)
Other 13% (2)
Third-line treatments?
Other 27% (4)
Dapsone 20% (3)
Ciclosporin 13% (2)
Methotrexate 13% (2)
Mycophenolate mofetil 13% (2)
If you use any of the listed
treatments in children, which ones do you use?
Ciclosporin 80% (4)
Omalizumab 80% (4)
Azathioprine 60% (3)
Dapsone 60% (3)
Mycophenolate mofetil 60% (3)
Methotrexate 20% (1)
Section 3: Use of standardized measures
Do you use standardized
measures when assessing disease?
Yes 84% (16)
No 16% (3)
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Activity Score (UAS-7, 63%), the Physician Global Assess-
ment (63%), the Patient Global Assessment (44%) and the
Dermatology Quality of Life Index (DLQI) (38%). Guidelines
are used by 89% to direct their management of CSU, with
50% using the EAACI/GA2LEN/EDF/WAO guideline,1
compared with 31% primarily using the BSACI guideline.2
The main perceived barriers to prescribing systemic medi-
cations were potential adverse effects (AEs) (32% strongly
agreed), potential long-term toxicity (26% strongly agreed),
cost of treatment (42% strongly agreed), and views
expressed by the patient and their family (37% agreed).
Our findings show variance between dermatology,
allergy and immunology consultants with regard to the
prescribing of systemic agents in CSU (Fig. 2). Our findings
suggest that allergists are more likely to prescribe omal-
izumab as first-line treatment, whereas dermatologists more
commonly prescribe ciclosporin, which is not in keeping
with National Institute for Care Excellence guidance.3
Drug-related AEs are the main perceived barrier for clin-
icians to prescribe systemic medications. Other barriers to
prescribing are the cost of medications. The list price for
omalizumab 300 mg monthly for 12 months is £6150,4
excluding the cost of post-injection observations required
in a secondary care setting, whereas ciclosporin (in generic
formulation) costs £2660 for 12 months (300 mg/day;
4 mg/kg/day for a patient weighing 75 kg),4 excluding
the cost of renal function and blood-pressure monitoring.
The main limitation to our survey was the number of
respondents, as we chose to focus on consultant physicians
with a specialist interest in urticaria.
In summary, our UK survey highlights the differences
in management of CSU between dermatologists and other
specialists, resulting in variation in the care provided for
patients with CSU. Although national and international
treatment guidelines now recommend omalizumab as a
Table 1. continued
Parameter Response, % (n)
Physician Global Assessment
Most of the time 63% (10)
Sometimes 13% (2)
Never 25% (4)
Patient Global Assessment
Most of the time 44% (7)
Sometimes 25% (4)
Rarely 6% (1)
Never 25% (4)
UAS-7
Most of the time 63% (10)
Sometimes 38% (6)
In-clinic UAS
Most of the time 25% (4)
Sometimes 13% (2)
Rarely 19% (3)
Never 44% (7)
Angio-oedema Activity Score
Sometimes 44% (7)
Rarely 25% (4)
Never 31% (5)
Itch severity score
Most of the time 13% (2)
Sometimes 19% (3)
Rarely 31% (5)
Never 38% (6)
Weekly number of hives score
Most of the time 13% (2)
Sometimes 25% (4)
Rarely 19% (3)
Never 44% (7)
DLQI
Most of the time 38% (6)
Sometimes 25% (4)
Rarely 25% (4)
Never 13% (2)
CU-Q2oL
Sometimes 25% (4)
Rarely 25% (4)
Never 50% (8)
AE-QoL
Sometimes 6% (1)
Rarely 31% (5)
Never 63% (10)
Section 4: Use of guidelines and perceived barriers
Do you use guidelines to direct
your management of urticaria?
Yes 89% (17)
No 11% (2)
Which guidelines do you refer to?
EACCI/GA(2)LEN/EDF/WAO 50% (8)
Other 38% (6)
Local guidelines 13% (2)
Support services for patients
Access to nursing support 89% (16)
Access to inpatient facilities 61% (11)
Dedicated urticaria service 56% (10)
Nurse prescribers 28% (5)
Main perceived barriers to
prescribing systemic medications
Cost
Side effects of treatments
Views expressed by patient or family
Long-term toxicity
Azathioprine
Ciclosporin
Dapsone
Methotrexate
Mycophenolate Mofetil
Omalizumab
Other
0%
First Line Second Line Third Line Not Used
30%20%10% 40% 50% 60% 70% 90%80% 100%
Figure 1 First-, second- and third-line systemic drug selection.
AE-QoL, Angioedema Quality of Life Questionnaire; CU-Q2oL,
Chronic Urticaria Quality of Life Questionnaire EACCI/GA(2)LEN/
EDF/WAO, European Academy of Allergy and Clinical Immunology,
Global Allergy and Asthma European Network. European Dermatol-
ogy Forum and World Allergy Organization; DLQI, Dermatology Life
Quality Index; UAS7, weekly Urticaria Activity Score.
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first-line agent for severe CSU not responding to antihis-
tamine and montelukast treatment, these guidelines are
based on placebo-controlled studies. The current lack of
head-to-head comparisons between conventional systemic
and biologic therapies may explain some of the variation
in treatment approaches we observed, and highlights the
need for further research in this area, including a com-
prehensive health economics evalation.3,5
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Figure 2 First-, second- and third-line systemic drug selection by
specialty.
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